These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1988231)

  • 1. Immunogenicity of surfactant. II. Porcine and bovine surfactants.
    Strayer DS; Hallman M; Merritt TA
    Clin Exp Immunol; 1991 Jan; 83(1):41-6. PubMed ID: 1988231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of surfactant. I. Human alveolar surfactant.
    Strayer DS; Hallman M; Merritt TA
    Clin Exp Immunol; 1991 Jan; 83(1):35-40. PubMed ID: 1988229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo and in vitro inactivation of bovine surfactant by an anti-surfactant monoclonal antibody.
    Eijking EP; Strayer DS; van Daal GJ; Tenbrinck R; Merritt TA; Hannappel E; Lachmann B
    Eur Respir J; 1991 Nov; 4(10):1245-50. PubMed ID: 1804672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.
    Wang Z; Chang Y; Schwan AL; Notter RH
    Am J Respir Cell Mol Biol; 2007 Oct; 37(4):387-94. PubMed ID: 17556674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of anti-curosurf antibodies to understanding the biology of alveolar surfactant.
    Strayer DS
    Biol Neonate; 1992; 61 Suppl 1():2-14. PubMed ID: 1327194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations.
    Seeger W; Grube C; Günther A; Schmidt R
    Eur Respir J; 1993 Jul; 6(7):971-7. PubMed ID: 8370446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody to surfactant protein A increases sensitivity of pulmonary surfactant to inactivation by fibrinogen in vivo.
    Strayer DS; Herting E; Sun B; Robertson B
    Am J Respir Crit Care Med; 1996 Mar; 153(3):1116-22. PubMed ID: 8630554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural vs synthetic surfactants in neonatal respiratory distress syndrome.
    Halliday HL
    Drugs; 1996 Feb; 51(2):226-37. PubMed ID: 8808165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity.
    Holm BA; Notter RH
    J Appl Physiol (1985); 1987 Oct; 63(4):1434-42. PubMed ID: 3693177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of surfactant function by copper-zinc superoxide dismutase (CuZn-SOD).
    Haddad IY; Nieves-Cruz B; Matalon S
    J Appl Physiol (1985); 1997 Nov; 83(5):1545-50. PubMed ID: 9375318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a cell membrane protein that binds alveolar surfactant.
    Strayer DS
    Am J Pathol; 1991 May; 138(5):1085-95. PubMed ID: 1850959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the immunogenicity and stability of a porcine pulmonary surfactant preparation administered in rabbits.
    Precioso AR; Sakae PP; Mascaretti RS; Kubrusly FS; Gebara VC; Iourtov D; Rebello CM; Vaz FA; Raw I
    Clinics (Sao Paulo); 2006 Apr; 61(2):153-60. PubMed ID: 16680333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral cell wall lipids of Mycobacterium tuberculosis are inhibitory to surfactant function.
    Wang Z; Schwab U; Rhoades E; Chess PR; Russell DG; Notter RH
    Tuberculosis (Edinb); 2008 May; 88(3):178-86. PubMed ID: 18155644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biophysical activity of animal-derived exogenous surfactants mixed with rifampicin.
    Kolomaznik M; Calkovska A; Herting E; Stichtenoth G
    Adv Exp Med Biol; 2015; 839():31-9. PubMed ID: 25252905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance of different surfactant preparations to inactivation by meconium.
    Herting E; Rauprich P; Stichtenoth G; Walter G; Johansson J; Robertson B
    Pediatr Res; 2001 Jul; 50(1):44-9. PubMed ID: 11420417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future.
    Sardesai S; Biniwale M; Wertheimer F; Garingo A; Ramanathan R
    Pediatr Res; 2017 Jan; 81(1-2):240-248. PubMed ID: 27706130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exogenous porcine surfactant (Curosurf) is inactivated by monoclonal antibody to the surfactant-associated hydrophobic protein SP-B.
    Kobayashi T; Robertson B; Grossmann G; Nitta K; Curstedt T; Suzuki Y
    Acta Paediatr; 1992 Sep; 81(9):665-71. PubMed ID: 1421904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome.
    Wiseman LR; Bryson HM
    Drugs; 1994 Sep; 48(3):386-403. PubMed ID: 7527760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenicity of low molecular weight surfactant species.
    Strayer DS; Merritt TA; Makunike C; Hallman M
    Am J Pathol; 1989 Apr; 134(4):723-32. PubMed ID: 2705504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of mycobacterial lipids on surface properties of Curosurf: implications for lung surfactant dysfunction in tuberculosis.
    Chimote G; Banerjee R
    Respir Physiol Neurobiol; 2008 Jun; 162(1):73-9. PubMed ID: 18515195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.